DALLAS, Sept. 24, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring stem-cell therapeutic company Osiris Therapeutics Inc. (Nasdaq:OSIR). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.

The investment report on Osiris Therapeutics Inc. (Nasdaq:OSIR) should be of particular interest to biotechnology companies: Genzyme Corp. (Nasdaq:GENZ), Biogen Idec Inc. (Nasdaq:BIIB), Advanced Cell Technology Inc. (Pink Sheets:ACTC) and Cytori Therapeutics Inc. (Nasdaq:CYTX).

The full report is available at: http://www.stockpreacher.com/n/OSIR

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher

Osiris Therapeutics Inc. (OSIR), a stem cell therapeutic company, engages in the development and marketing of products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Working on cellular therapies based on stem cells isolated from readily available adult bone marrow, OSIR looks to provide revolutionary treatments for a number of life-threatening conditions.

Message Board Search for OSIR: http://www.boardcentral.com/boards/OSIR

In the report, the analyst notes:

"OSIR recently disclosed its Prochymal drug for bone-marrow transplant patients failed two late-stage studies, with neither trial reaching its primary endpoint, significantly eroding the Company's share price by 34%.

"According to the trial's key findings, there was no statistical difference between Prochymal and placebo on the primary endpoints for either the steroid-refractory or the first line GvHD trials. When the drug was used on patients not benefiting from steroids in the second trial, it did not show statistically significant improvement. The majority of patients in the trial were suffering from skin GvHD, which responded significantly better to steroids than had been previously reported in controlled trials.

"While Prochymal may have caused a setback, the Company is nonetheless looking forward to advancing the drug's several other indications. During the second quarter of 2009, the Company announced it was working with the FDA as it expanded the phase II type 1 diabetes trial to include pediatric patients. It also created a new Biosurgery Division focused on developing high end biologic products for use in surgical procedures. The Company is also reportedly moving forward with collaboration with Genzyme for the potential application of Prochymal in Acute Radiation Syndrome (ARS)."

To read the entire report visit: http://www.stockpreacher.com/n/OSIR

StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.

CONTACT: StockPreacher.com
         Jeff Bishop
         (469)-252-3505
         press@beaconequity.com